MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
DexCom Operating Expenses 2011-2026 | DXCM
Annual Operating Expenses DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 B | 1.84 B | 1.69 B | 1.49 B | 1.41 B | 981 M | 789 M | 850 M | 535 M | 442 M | 336 M | 198 M | 129 M | 102 M | 80.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 B | 80.7 M | 851 M |
Quarterly Operating Expenses DexCom
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 476 M | 455 M | - | 442 M | 469 M | 461 M | - | 418 M | 418 M | 415 M | - | 347 M | 372 M | 357 M | - | 329 M | 316 M | 298 M | - | 246 M | 216 M | 223 M | 208 M | 191 M | 207 M | 183 M | 387 M | 155 M | 158 M | 150 M | 142 M | 128 M | 131 M | 134 M | 123 M | 120 M | 106 M | 94.3 M | 89.6 M | 117 M | 69.6 M | 59.2 M | 57.8 M | 52.2 M | 45.7 M | 42.1 M | 36.4 M | 33.4 M | 31.8 M | 27.4 M | 25.9 M | 25.7 M | 25.9 M | 24.8 M | 22.9 M | 21.5 M | 19.3 M | 17 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 476 M | 17 M | 183 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.99 B | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
411 M | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
50.6 M | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
59.5 M | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
607 M | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Interpace Biosciences
IDXG
|
20 M | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
6.71 B | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
3.69 B | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 15.3 | 6.03 % | $ 463 M | USA |
 |
Guardant Health
GH
|
226 M | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
9.98 M | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Medpace Holdings
MEDP
|
118 M | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
Biomerica
BMRA
|
5.64 M | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 28.55 | 0.87 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Celcuity
CELC
|
172 M | $ 120.4 | 2.78 % | $ 5.63 B | USA |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
NeoGenomics
NEO
|
430 M | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
1.48 B | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
Natera
NTRA
|
258 M | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
5.76 M | $ 5.19 | 5.06 % | $ 4.08 M | USA |
 |
National Research Corporation
NRC
|
38.5 M | $ 16.82 | 2.03 % | $ 376 M | USA |
 |
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
600 M | $ 1.45 | 8.21 % | $ 435 M | USA |
 |
Psychemedics Corporation
PMD
|
11.3 M | - | -1.84 % | $ 15.3 M | USA |